Copyright
©The Author(s) 2017.
World J Gastroenterol. Sep 28, 2017; 23(36): 6549-6570
Published online Sep 28, 2017. doi: 10.3748/wjg.v23.i36.6549
Published online Sep 28, 2017. doi: 10.3748/wjg.v23.i36.6549
Table 1 Treatment options for alcoholic liver disease and alcoholic steatohepatitis
| General management |
| Abstinence |
| Nutritional support |
| Glucocorticosteroids |
| Pentoxifylline |
| Anti-TNF therapy |
| Antioxidants |
| Liver transplantation |
| Potential new therapies |
| Probiotics and antibiotics |
| S-adenosylmethionine |
| Betaine |
| Targeting various chemokines and interleukins |
| Endocannabinoids antagonists |
| Osteopontin inhibition |
| Stem cell therapy |
Table 2 Treatment options for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
| Lifestyle changes | Weight loss |
| Dietary changes | |
| Exercise | |
| Insulin sensitizers | Thiazolidinedione’s |
| Metformin | |
| Lipid lowering agents | Statins |
| Ezetimibe | |
| Hepatoprotective agents | UDCA |
| Antioxidants | Vitamin E |
| Incretin analogues | GLP-1 agonists |
| DPP-IV inhibitors | |
| Anti-inflammatory agents | PTX |
| Others | Probiotics |
| Angiotensin receptor blockers | |
| Endocannabinoid antagonists | |
| Bariatric surgery | |
| Liver transplantation | |
| Potential new therapeutic options | Caspases inhibitors |
| ASK1 inhibitors | |
| p38 MAPK inhibitors | |
| PPAR- alpha and delta agonists | |
| FXR agonists | |
| NOX-1/4 inhibitors | |
| Galectin-3 antagonists | |
| Acetyl CoA carboxylase inhibitors | |
| FGF-21 and FGF-19 analogues | |
| CCR2 and CCR5 inhibitors | |
| SCD-1 inhibitors | |
| Lysyl oxidase-like 2 inhibitors | |
| Sirtuins |
- Citation: Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol 2017; 23(36): 6549-6570
- URL: https://www.wjgnet.com/1007-9327/full/v23/i36/6549.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i36.6549